Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Liquidia Corp (LQDA)

Liquidia Corp (LQDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,003,937
  • Shares Outstanding, K 86,995
  • Annual Sales, $ 14,000 K
  • Annual Income, $ -130,390 K
  • EBIT $ -107 M
  • EBITDA $ -105 M
  • 60-Month Beta 0.48
  • Price/Sales 214.63
  • Price/Cash Flow N/A
  • Price/Book 136.22

Options Overview Details

View History
  • Implied Volatility 91.47% (-0.23%)
  • Historical Volatility 54.20%
  • IV Percentile 62%
  • IV Rank 36.33%
  • IV High 185.25% on 10/31/25
  • IV Low 37.96% on 01/23/25
  • Expected Move (DTE 5) 2.57 (7.43%)
  • Put/Call Vol Ratio 0.76
  • Today's Volume 11,032
  • Volume Avg (30-Day) 6,530
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 185,101
  • Open Int (30-Day) 183,272
  • Expected Range 31.96 to 37.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.08
  • Number of Estimates 5
  • High Estimate 0.29
  • Low Estimate -0.08
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +117.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.76 +24.39%
on 11/21/25
35.54 -2.84%
on 12/09/25
+4.89 (+16.50%)
since 11/19/25
3-Month
21.15 +63.30%
on 09/26/25
35.54 -2.84%
on 12/09/25
+10.75 (+45.21%)
since 09/19/25
52-Week
10.51 +228.54%
on 12/20/24
35.54 -2.84%
on 12/09/25
+23.94 (+226.06%)
since 12/19/24

Most Recent Stories

More News
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases,...

LQDA : 34.53 (+2.55%)
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Recorded $51.7 million in net product sales of YUTREPIAâ„¢ as launch momentum continues Achieved profitability in the first full quarter of YUTREPIA sales More than 2,000 unique patient prescriptions...

LQDA : 34.53 (+2.55%)
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced...

LQDA : 34.53 (+2.55%)
Bank of America Securities Sticks to Their Buy Rating for Liquidia Technologies (LQDA)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Liquidia Technologies, with a price target of $37.00. The company’s shares closed yesterday at $24.08.Elevate...

LQDA : 34.53 (+2.55%)
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025

MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today...

LQDA : 34.53 (+2.55%)
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting

MORRISVILLE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced...

LQDA : 34.53 (+2.55%)
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium

MORRISVILLE, N.C., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,...

LQDA : 34.53 (+2.55%)
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference

MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the...

LQDA : 34.53 (+2.55%)
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILD Positive interim data from ASCENT trial reinforces YUTREPIA’s tolerability...

LQDA : 34.53 (+2.55%)
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025

MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease,...

LQDA : 34.53 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Liquidia Corporation is a biopharmaceutical company. It develops, manufactures and commercializes products for unmet patient needs principally in the United States. Liquidia Corporation, formerly known as LIQUIDIA TECHNL, is based in Morrisville, North Carolina.

See More

Key Turning Points

3rd Resistance Point 36.80
2nd Resistance Point 35.98
1st Resistance Point 35.26
Last Price 34.53
1st Support Level 33.72
2nd Support Level 32.90
3rd Support Level 32.18

See More

52-Week High 35.54
Last Price 34.53
Fibonacci 61.8% 25.98
Fibonacci 50% 23.03
Fibonacci 38.2% 20.07
52-Week Low 10.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar